EGFR activation by EGF stimulation or mutation can decrease the expression of PD-L1 in cancer cells through the p-ERK1/2/p-c-Jun pathway, which plays an important role in the platelet-induced upregulation of PD-L1 in tumor cells [42]. Here, MAPK3 is linked to neoplasm.